Principal component 1 and principle component 2 by cancer stage.

<p>Principal component 1 and principle component 2 by cancer stage.</p

Baseline Characteristics and Follow-up Duration.

<p>* ACT was checked only in the heparin arm</p><p>^† 32% of patients had non-ST-elevation myocardial infarction</p><p>^‡ Elective in patients with high bleeding risk</p><p>^§ Elective in patients with high ischemic risk</p><p>Data are formatted as bivalirudin arm/ heparin arm</p><p>ACS = acute coronary syndrome; ACT = activated clotting time; DM = diabetes mellitus; MI = myocardial infarction; NSTEMI = Non-ST-elevation myocardial infarction; NR = not reported; PCI = percutaneous coronary intervention; SD = standard deviation; STEMI = ST-elevation myocardial infarction.</p><p>Baseline Characteristics and Follow-up Duration.</p

Study Medications.

<p>* Prasugrel and ticagrelor combined together</p><p>^† Enoxaparin 1 mg/kg twice daily could be used instead of unfractionated heparin</p><p>Data are formatted as bivalirudin arm/ unfractionated heparin arm</p><p>ADP = adenosine diphosphate; ASA = aspirin; NR = not reported; PCI = percutaneous coronary intervention</p><p>Study Medications.</p

Study selection flow diagram.

<p>Summary of how the systematic search was conducted and eligible studies were identified. ACC = American College of Cardiology; ADP = adenosine diphosphate; AHA = American Heart Association; ESC = European Society of Cardiology; GP IIb/IIIa = glycoprotein IIb/IIIa; MeSH = Medical Subject Headings; TCT = Transcatheter Cardiovascular Therapeutics.</p

Comparison of Summary Estimates for Study Outcomes.

<p>CI = Confidence interval; MACE = major adverse cardiac events; MI = myocardial infarction; NACE = net adverse clinical events; OR = odds ratio; P = Peto method; SGS = Shuster, Guo, and Skyler method; UFH = unfractionated heparin.</p><p>Comparison of Summary Estimates for Study Outcomes.</p

Summary plot of stent thrombosis for bivalirudin versus heparin according to acute coronary syndrome versus elective cases.

<p>The relative size of the data markers indicates the weight of the sample size from each study. ACS = acute coronary syndrome; CI = confidence interval; OR = odds ratio.</p

Summary plot of major bleeding for bivalirudin arm versus heparin according to doses ≤ 75 units/kg versus doses ≥ 100 units/kg.

<p>The relative size of the data markers indicates the weight of the sample size from each study. CI = confidence interval; OR = odds ratio.</p

Additional file 1: of Perceptions of patients and providers on myocardial perfusion imaging for asymptomatic patients, choosing wisely, and professional liability

Patient Survey. Description: Full version of questionnaire given to patients. (DOCX 25 kb

Additional file 2: of Perceptions of patients and providers on myocardial perfusion imaging for asymptomatic patients, choosing wisely, and professional liability

Provider Survey. Description: Full version of questionnaire given to providers. (DOCX 27 kb

IDB induces megakaryocytic differentiation of human CD34+ progenitors whereas PMA does not.

<p><b>(A–C, upper panels)</b> Morphology of adult human CD34+ hematopoietic progenitors cultured for 7 days in medium containing TPO and SCF alone or with 10 nM IDB or 10 nM PMA on Wright-stained preparations. Note that relative to control cells, cells treated with IDB were larger and had polyploid nuclei. <b>(A–C, lower panels)</b> Adult human CD34+ progenitors were treated with TPO and SCF with or without 10 nM IDB or 10 nM PMA. After 7 days of culture, the cells were stained with a fluorescent antibody directed against CD41a (open profiles) or with an isotype matched control antibody (black profiles). All flow cytograms in this and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0051059#pone-0051059-g002" target="_blank">Figures 2</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0051059#pone-0051059-g003" target="_blank">3</a> are representative of at least 3 independent runs. (D) Adult human CD34+ progenitors were treated with TPO and SCF with 25 nM IDB, 10 nM PMA, 100 nM PMA, or 1 µM Mezerein. After 7 days of culture, the cells were stained with a fluorescent antibody directed against CD41a (open profiles) or with an isotype matched control antibody (black profiles).</p